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ABSTRACT 
Following the first isolation of their genes, genetic diseases of nuclear receptors were initially 
discovered by a candidate gene approach based on their known roles in endocrine pathways and 
physiological processes. Subsequently, the identification of disorders has been informed by 
phenotypes associated with gene disruption in animal models or by genetic linkage studies. More 
recently, whole exome sequencing has associated pathogenic genetic variants with unexpected, 
often multisystem, human phenotypes. To date, defects in 20 out of 48 human NR genes have been 
associated with human disorders, with different mutations mediating phenotypes of varying severity 
or several, distinct conditions being associated with different changes in the same gene. Studies of 
individuals with deleterious genetic variants can elucidate novel human roles of NRs, validating them 
as targets for drug development, or providing new insights into structure-function relationships. 
Importantly, human genetic discoveries enable definitive disease diagnosis and can provide 
opportunities therapeutically manage affected individuals. Here, we review germline changes in 
human NR genes associated with “monogenic” conditions, including a discussion of the structural 
basis of mutations that cause distinctive changes in nuclear receptor function and molecular 
mechanisms mediating pathogenesis. 
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INTRODUCTION 
It has been almost 30 years since the first human nuclear receptor (NR) disorders were characterized 
at the molecular level (Figure 1). Since then, disorders associated with genetic defects in 20 out of 
the 48 known human NRs have been identified (Figure 1, Tables 1 & 2). In this review, we provide a 
brief overview of the range of human NR-associated conditions reported to date, and highlight some 
of the key pathogenic mechanisms involved (Figure 2A). Our focus is on well-established, germline, 
monogenic disorders. We will not cover the role of somatic NR variations or fusion genes in cancer, 
nor associations found in genome-wide association studies.  
 
Thyroid hormone receptor α and -β (NR1A1 and -2)  
Thyroid hormones (TH) regulate physiological processes (skeletal growth, maturation of the CNS, 
heart rate and contractility, energy expenditure) via receptors (TRα1, TRβ1, TRβ2) encoded by 
separate genes (THRA/NR1A1, THBR/NR1A2 ), with differing tissue distributions: TRα1 is highly 
expressed in the CNS, myocardium, gastrointestinal tract and skeletal muscle; TRβ1 is the 
predominant isoform in liver and kidney; TRβ2 expression is restricted principally to the 
hypothalamus, pituitary, retina and inner ear. Such divergence of receptor subtype expression likely 
mediates distinctive phenotypes associated with defective THRB or THRA. 
 
Resistance to THβ (RTHβ), usually dominantly inherited, is recognized by a characteristic biochemical 
signature of elevated circulating TH and non-suppressed thyroid-stimulating hormone (TSH) levels, 
reflecting central (hypothalamic-pituitary) resistance to TH action, together with variable resistance 
in peripheral tissues. Approximately 160 different, heterozygous THRB mutations, which are  
localized in the ligand binding domain (LBD) and involve both TRβ2 and TRβ1 isoforms, have been 
identified in the disorder (1). 
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Affected individuals can have nonspecific symptoms or a goiter, prompting thyroid function tests 
that suggest the diagnosis; these individuals are deemed to have generalized resistance to TH 
(GRTH). In approximately 15% of cases the same biochemical picture can be associated with 
thyrotoxic features (e.g. weight loss, tremor, anxiety, tachycardia in adults; failure to thrive and 
hyperkinetic behaviour in children); disproportionate resistance to TH in TRβ-expressing 
hypothalamus and pituitary (PRTH), with relative retention of hormone sensitivity in TRα-expressing 
peripheral tissues, may account for this phenotype. GRTH and PRTH phenotypes can be associated 
with the same TRβ mutation and even coexist within a single family. Other recognized features of 
the disorder include attention-deficit hyperactivity disorder in childhood and dyslipidemia and 
reduced bone mineral density in adults (1). 
 
Consonant with their location, most TRβ mutations impair hormone binding or (rarely) coactivator 
recruitment and inhibit action of their wild-type counterparts in a dominant-negative manner 
(Figure 2B). Receptor functional regions (DNA binding, dimerization, corepressor binding) are devoid 
of naturally occurring TRβ mutations, with RTHβ variants clustering within hotspots within the LBD 
(1). Homozygous THRB deletion mediates RTHβ in the first two recorded siblings with this disorder, 
who also had audiovisual abnormalities (2), and missense mutations in five other recessively 
inherited cases (3). In roughly 15% of people with typical biochemical features of RTHβ, no THRB 
defect can be identified; here, alterations in coregulators or other factors mediating TH action, have 
been postulated (1). Triiodothyroacetic acid (TRIAC) treatment, a centrally acting TH analogue that 
lowers TH levels, can control thyrotoxic features of the disorder.  
 
Resistance to THα (RTHα), characterised by features of hypothyroidism in selected tissues, eluded 
discovery probably because thyroid function tests are near-normal in the disorder. Most cases have 
been identified in childhood, with features including disproportionate (lower segment) growth 
retardation, macrocephaly, dysmorphic features, constipation, dyspraxia and intellectual deficit. 
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Biochemical abnormalities include low/low-normal thyroxine (T4) and high/high-normal 
triiodothyronine (T3) computing to a low T4/T3 ratio, variably reduced reverse T3, elevated muscle 
creatine kinase levels, and anemia (4, 5). 
 
Heterozygous THRA mutations disrupt TRα1 function either markedly or partially and inhibit wild-
type receptor action in a dominant-negative manner via a mechanism involving enhanced 
corepressor recruitment and target gene repression (Figure 2B; Figure 3A) (5). Some THRA defects 
also involve the carboxyterminally divergent, non-hormone-binding TRα2 isoform, with no 
discernible added clinical phenotype or gain- or loss-of-function attributable to the TRα2 variant (6). 
Consonant with resemblance of the RTHα phenotype with some features of conventional 
hypothyroidism, T4 therapy reverses metabolic abnormalities and also improves growth, 
constipation, dyspraxia and well-being.  
 
Vitamin D receptor (NR1I1/VDR) 
The principal role of the vitamin D receptor (VDR) is in regulation of calcium and phosphate 
metabolism with actions in the gastrointestinal tract, kidney and bone. Hypocalcemia and associated 
symptoms (skeletal and respiratory muscle weakness, seizures) in the early neonatal period or 
infancy due to lack of VDR-dependent intestinal calcium absorption dominates the phenotype of 
autosomal recessive, hereditary, vitamin D-resistant rickets (HVDRR) (also known as vitamin D-
dependent rickets type II). Rickets manifests with bone pain, growth restriction and fractures; low 
circulating calcium and phosphate with raised alkaline phosphatase are associated with normal 
serum 25-hydroxy but very elevated 1,25 dihydroxyvitamin D3 (calcitriol) levels and secondary 
hyperparathyroidism and raised parathyroid hormone levels. Alopecia (patchy or total) affecting 
both scalp and body is a distinctive, non-osseous feature of the disorder. 
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Approximately 100 cases of HVDRR harboring ~45 different homozygous or compound heterozygous 
VDR mutations have been recorded: frameshift, premature-stop and DNA-binding domain (DBD) 
mutations lead to complete loss-of-function. Additionally, approximately 20 LBD variants exhibit 
either reduced ligand binding, failure to heterodimerize with RXR, or selective loss of coactivator 
recruitment (Figure 3B); a single HVDRR case lacking a VDR mutation has also been described (7). In 
one family, a missense VDR mutation (p. Glu420Ala), which abolished coactivator binding and 
exhibited dominant-negative activity, mediated HVDRR in the heterozygous state (8). Patients with 
HVDRR require oral or intravenous calcium therapy; high-dose vitamin D or calcitriol treatment can 
overcome the receptor defect in LBD mutation cases (7), raising the possibility of structure-guided 
design of synthetic analogues for treatment of a subset of HVDRR (9). 
 
Interestingly, alopecia occurs in patients with VDR mutations that lead to loss of receptor 
expression, DNA binding or dimerization, but are not a feature in cases with ligand binding or 
coactivator recruitment defects. This abnormality is unresponsive to calcitriol therapy, leading to the 
hypothesis that inhibition of target genes by unliganded, wild-type VDR maintains normal cycling of 
hair follicles, with loss of such repression mediating hair loss (Figure 2C). Supporting this notion, 
mutations in Hairless (HR), a known component of NR repression complexes, also cause an alopecia 
syndrome (atrichia with papules) (10). 
 
Glucocorticoid receptor α (NR3C1) 
Disruption of glucocorticoid receptor α (GRα, encoded by NR3C1) is associated with familial 
glucocorticoid resistance (FGR, also known as generalized glucocorticoid resistance or Chrousos 
syndrome) (11, 12). This can be dominantly or recessively inherited, with a range of features 
depending on the severity of the defect or underlying molecular mechanism. Individuals with FGR 
often present with fatigue, but other signs of glucocorticoid insufficiency are rare. Because of 
reduced central feedback, adrenocorticotropic hormone (ACTH) is elevated, increasing cortisol and 
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partly compensating for glucocorticoid resistance. One consequence of elevated ACTH is an increase 
in adrenal mineralocorticoid and androgen production. Consequently, clinical and biochemical 
features of FGR can include hypertension, hypokalemia and metabolic alkalosis, as well as hirsutism, 
acne, male-pattern baldness, oligomenorrhea and infertility.  
 
Most pathogenic missense variants in GRα are located in the LBD and affect glucocorticoid binding 
or transactivation. Patients or carriers with heterozygous changes tend to have a milder phenotype, 
although dominant-negative LBD variants have been reported (p.Ile559Asn, Ile747Met) (13, 14). LBD 
mutants often show variably reduced ligand binding affinity, as well as delayed nuclear translocation 
and altered interactions with coactivators (e.g. p160) (14). Clinical and biochemical features in 
individuals with homozygous mutations in NR3C1 are usually more severe. No familial “activating” 
mutations in GRα have been reported, but a heterozygous variant (p.Asp410His) has been reported 
in a woman with features of tissue-selective glucocorticoid hypersensitivity (e.g. visceral obesity, 
dyslipidemia, type 2 diabetes (T2D), hypertension) (15). This mutant receptor increased 
transactivation of glucocorticoid-responsive genes.  
 
Mineralocorticoid receptor (NR3C2)  
The mineralocorticoid receptor (MR, encoded by NR3C2) plays a key role in renal sodium retention 
and cardiovascular endocrinology. Pathogenic loss-of-function variants in this receptor are 
associated with a renal form of mineralocorticoid resistance known as autosomal-dominant (or 
sporadic) pseudohypoaldosteronism type 1 (PHA I) (16, 17). Children typically present in early 
infancy with dehydration and failure to thrive, and have hyponatremia, hyperkalemia, and elevated 
aldosterone levels and plasma renin activity (PRA). Some infants with elevated aldosterone and PRA 
are asymptomatic. Sodium supplementation is usually required, but the condition improves in 
childhood. In contrast, the autosomal recessive form of PHA I, due to defects in the amiloride-
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sensitive epithelial sodium channel (ENaC), is a more severe systemic condition that does not remit 
with age.  
 
Pathogenic MR mutations include nonsense, frameshift, splice and missense mutations, with a 
potential hotspot at c.2839C>T (p.Arg947*). Missense mutations often affect key amino acids in the 
LBD and impair aldosterone binding and aldosterone-dependent transactivation (16, 18). Nuclear 
localization can sometimes be affected and different variants may have differential effects on MR-
target genes (e.g. SGK1, NDRG2, GILZ, SCNN1A) (18, 19).  
 
A gain-of-function MR variant was reported in 2000, in one family with early-onset hypertension 
(before the age of 20) (20). Females also exhibited marked hypertension during pregnancy. The 
heterozygous p.Ser810Leu variant identified in affected family members showed mild constitutive 
activity together with inappropriate responsiveness to progesterone. The leucine substitution at 
position 810 increases van der Waals interactions and lessens hydrogen bonding with steroid side 
groups, thereby enabling progesterone to bind and activate mutant MR (Figure 3C). Although this 
germline mutation is rare, it exemplifies how genetic variants in NRs can potentially alter ligand 
specificity; such altered ligand specificity is well recognized with somatic ERα variants in breast 
cancer or androgen receptor (AR) mutations in prostate cancer.  
 
Estrogen Receptor α (NR3A1) 
ERα (encoded by ESR1) is one of the best-studied NRs in human biology. To date, only three genomic 
pathogenic variants associated with a clear phenotype have been reported; however, these cases do 
provide important insight into the role of ERα in human development and health. 
 
The first report of a pathogenic ESR1 variant in 1994 involved a 28-year-old man who presented with 
tall stature (204cm), prolonged linear growth, delayed epiphyseal fusion and reduced bone mineral 
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density (z-score -3.1) (21, 22). He had normal puberty, but had elevated follicular stimulating 
hormone (FSH) and luteinizing hormone (LH) levels and reduced sperm viability. He also had 
impaired glucose tolerance, hyperinsulinemia and an abnormal lipid profile with evidence of early 
coronary atherosclerosis, although his BMI was elevated (30.5 kg/m2). Genetic analysis revealed a 
homozygous stop gain variant (p.Arg157*). He had mildly elevated serum estradiol and resistance to 
estrogen treatment.  
 
In 2013, the first female with estrogen resistance was reported (23). This 18-year-old woman 
presented with absent breast development, primary amenorrhea and abdominal pain due to 
hemorrhagic ovarian cysts. She had a small uterus with no endometrium, but did have evidence of 
androgenization. Her bone age was markedly delayed (> 4 years), she did not have a pubertal growth 
spurt, and her bone density was reduced (z-score -2.4) with elevated markers of osteoblastic activity. 
Her estradiol was very elevated (10-fold above normal) with elevated inhibin A and mildly raised 
gonadotropins, and she was resistant to estrogen treatment. Analysis of ESR1 revealed a 
homozygous missense variant (p.Gln375His) in the LBD that impaired estrogen responsiveness in 
cell-based assays. Most recently, the first family with estrogen resistance (p.Arg394His) has been 
reported (24). 
 
These reports provide important information about the role of ERα in humans. As expected, ERα 
mediates the main effects of estrogen on bone growth and mineralization, as well as breast and 
uterine development in females. As in ER knockout mice, gonadotropin concentrations are higher in 
males, possibly because very high estradiol and inhibin A levels in females partly mediate central 
feedback. Finally, the woman described above had no evidence of hyperinsulinemia or glucose 
intolerance, but she had a low BMI (16.6 kg/m2) and body fat (28%). Long-term monitoring is 
needed to see if metabolic abnormalities develop, although the difference in BMI between the two 
individuals may be a factor influencing insulin sensitivity.  
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Androgen Receptor (NR3C4)  
Disruption of the AR results in androgen insensitivity syndrome (AIS) (25). This X-linked condition 
was first reported in 1953, and historically called “testicular feminization syndrome” (26). Women 
with complete AIS (CAIS) typically present during late adolescence with primary amenorrhea. 
Subsequent investigations show an absent uterus, 46,XY karyotype and elevated testosterone 
concentrations. Breast development usually occurs in adolescence due to the aromatization of 
androgens to estrogens, but androgen-dependent pubic hair is often absent or sparse. Occasionally 
the diagnosis is made when testes are found during hernia repair in childhood or with karyotype 
analysis for another indication. As with most conditions, a spectrum of phenotypes can occur. Partial 
AIS (PAIS) typically presents with atypical genitalia or hypospadias in the newborn period, and 
gynecomastia is a common feature at adolescence in boys with this condition (27). Mild AIS (MAIS) 
has also been reported in men with oligospermic infertility (28). 
 
More than 800 different pathogenic variants in the AR have been reported. These changes include 
stop-gain, frameshift and missense variants that are distributed throughout the gene, and have been 
reviewed extensively elsewhere (http://androgendb.mcgill.ca/, 26, 29). Missense variants tend to 
affect important amino acids involved in DNA-binding or ligand interactions, but many different 
residues can be affected. Although some mutations associate more with complete or partial 
phenotypes, there can be overlap between the type and location of the change, its activity in in vitro 
assays and the degree of androgen insensitivity in affected individuals. Missense mutations in =the 
hydrophobic ligand-binding pocket of the LBD usually cause CAIS (26), while missense mutations in 
the large amino-terminal activation function domain (AF1) usually cause PAIS or MAIS. Of note, a 
subset of individuals thought to have AIS do not have variants in the AR gene, despite cultured 
genital fibroblasts showing androgen resistance in vitro (e.g. reduced dihydrotestosterone-induced 
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apolipoprotein D expression) (30). Disruption of AR-dependent co-factors or post-receptor signaling 
mechanisms have been proposed as the cause (AIS type II) (30). 
 
The AR is unusual as it has a variable number of polyglutamine and polyglycine repeats in the amino-
terminal region of the receptor. Expansion of the polyglutamine tract (to 38-65 CAG trinucleotide 
repeats) is associated with X-linked spinal and bulbar muscular atrophy (SBMA, also known as 
Kennedy disease) (31). This condition results from AR-polyglutamine toxicity; the mutant protein 
misfolds and aggregates in spinal cord motor neurons and muscle cells. SBMA can sometimes be 
associated with reduced androgen action, gynecomastia, low sperm count and testicular atrophy.  
REFERENCE 
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Steroidogenic factor-1 (NR5A1)  
Steroidogenic factor-1 (SF-1, NR5A1) was identified following the search for a common regulator of 
steroidogenic enzyme transcription. Complete deletion of Nr5a1 in the mouse resulted in adrenal 
agenesis, gonadal (testicular) dysgenesis with persistent Müllerian structures (uterus, upper vagina) 
in XY animals and variable defects in gonadotropin release, confirming SF-1 as a key player in adrenal 
and gonad biology. Subsequently, other metabolic features such as late-onset obesity and 
ventromedial hypothalamic abnormalities were reported. 
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The first descriptions of pathogenic loss-of-function variants in NR5A1 in humans were in 1999 and 
2002 (32, 33). These reports included two 46,XY girls with testicular dysgenesis, Müllerian structures 
and salt-losing primary adrenal insufficiency. The first child had a de novo, heterozygous change (p. 
Gly35Glu) in the “P-box” region of the SF-1 DBD that affected binding to and transcriptional 
activation of target gene response elements (32). Functional studies suggested this was largely a 
gene dosage-dependent competitive effect, although partial dominant-negativity was reported in 
some systems. The second child had a homozygous pathogenic change (p. Arg92Gln) affecting the 
“A-box” region of SF-1 DBD (33). SF-1 belongs to a small subgroup of nuclear receptors that bind to 
DNA as monomers rather than as homo- or heterodimers. The A-box region is involved in stabilizing 
monomeric binding through an interaction with the DNA minor groove. Thus, a heterozygous P-box 
change and homozygous A-box change may have similar phenotypes. 
 
The past decade has seen great increases in the number of reported pathogenic changes in NR5A1 
and also the spectrum of SF-1-associated conditions (34). More than 200 individuals and families are 
now described in the literature. Heterozygous loss-of-function variants in NR5A1 occur in 
approximately 15% of individuals with testicular dysgenesis and reduced androgen production, 
resulting in 46,XY differences/disorders in sex development (DSD) (35). Phenotypes can range from 
females with a 46,XY karyotype to boys with penoscrotal hypospadias or undescended testes. Milder 
variants in NR5A1 can be associated with a small subset of male factor infertility, sometimes with 
progressive endocrine dysfunction (36). Variants in NR5A1 are also associated with primary ovarian 
insufficiency (POI) in 46,XX women, although the age of onset and natural time course are highly 
variable (37). Although many variants occur de novo, around 30% can be carried and maternally 
transmitted as a sex-limited dominant trait. Because multiple members of a family may have 46,XY 
DSD with 46,XX females being at risk of POI, careful family history and counseling is important. Very 
rarely, mutations in NR5A1 can cause primary adrenal insufficiency in 46,XX girls. 
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Although true “gain-of-function” variants in SF-1 have not been reported, recent observations 
suggest that recurrent, heterozygous missense changes in codon 92 (p.Arg92Trp, p.Arg92Gln) of SF-1 
are associated with ovotestes or testes in individuals with a 46,XX karyotype (38). Several individuals 
or families of diverse genetic ancestry have been reported. This particular amino acid change may 
interfere with expression of DAX-1 (see below) through WNT signaling in the developing gonad, but 
the exact mechanism “switching” the ovary into a testis remains unclear (Figure 3D).  
 
DAX-1 (NR0B1)  
Dosage-sensitive sex-reversal, adrenal hypoplasia congenita critical region on the X chromosome, 
gene 1 (DAX-1, encoded by NR0B1) is an orphan nuclear receptor that lacks the typical NR DBD, but 
has an amino-terminal region motif comprising three 66-67 amino acid tandem repeats. Similar to 
SF-1, DAX-1 plays a key role in adrenal and reproductive development.  
 
DAX-1 disruption was first reported to cause X-linked adrenal hypoplasia congenita (AHC) in 1994 
(39, 40). Since then, more than 200 individuals or families have been reported to have pathogenic 
variants in NR0B1 (34). The classic features in males include primary adrenal insufficiency in early 
infancy or childhood, delayed or arrested puberty due to disordered gonadotropin release, and 
impaired spermatogenesis. 
 
Nonsense or frameshift variants in NR0B1 occur throughout the gene, whereas pathogenic missense 
variants tend to cluster in key areas of the ligand-like binding domain in regions that form the 
hydrophobic core of the protein (41). Few missense changes in the amino-terminal repeat structure 
of DAX-1 have been reported. Partial loss-of-function missense variants can be associated with a 
milder phenotype of delayed onset adrenal insufficiency in early adulthood, or partial 
hypogonadotropic hypogonadism (42). Surprisingly, milder phenotypes can also occur due to stop 
gain variants at the start of the protein (p. Trp37*, p.Trp39*); this effect is likely due to reinitiation of 
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translation of a truncated DAX-1 protein from a downstream methionine at codon 83 that remains 
partially functional (due to the repeat motif structure) and “rescues” the phenotype (43). 
 
Although DAX-1-associated conditions are well established, the exact biological role of DAX-1 
remains unclear. Many studies demonstrate that DAX-1 acts as a transcriptional repressor, 
potentially through a direct interaction with SF-1 (41). Indeed, duplication of the locus containing 
DAX-1 is associated with testicular dysgenesis, suggesting that it may act as an “anti-testis” gene. 
DAX-1 may play a role in regulating progenitor cell differentiation. Loss of DAX-1-dependent 
repression may result in premature differentiation of progenitor cells without appropriate expansion 
of cell numbers, ultimately resulting in tissue hypoplasia. Indeed, loss of DAX-1 can sometimes be 
associated with early puberty in humans, and transient adrenal hyper-responsiveness has been 
reported in Dax1 knockout mice (44). Whether these phenomena reflect the true biological basis of 
DAX-1 function is still unclear. 
 
Retinoic acid receptor-β (NR1B2) 
Retinoic acid receptor-β (RARB) is expressed in many tissues during development and deletion of 
Nr1b2 in mice causes multiple defects (e.g. CNS, vision, hearing, musculoskeletal, cardiovascular, 
gastrointestinal, pulmonary, renal) and high lethality. 
 
In 2013, the first pathogenic RARB variants were reported in patients with STRA6 mutation-negative 
syndromic microphthalmia and additional features such as diaphragmatic hernia, cardiac anomalies 
and pulmonary hypoplasia (PDAC syndrome). In one family, two siblings were found to be compound 
heterozygous for disruptive variants (p.Arg119*/p.Ile403SerfsTer15) (45). At least three other 
unrelated children with microphthalmia and one or more of these additional features have been 
found to carry de novo, heterozygous changes affecting an arginine hotspot at codon 387 (e.g. 
p.Arg387Ser, p.Arg387Cys), potentially mediating a gain-of-function mechanism (45, 46). Taken 
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together, these findings provide support for retinoic acid pathways in human eye development and 
organogenesis. Indeed, NR1B2 is highly expressed in the human retina, unlike NR1B1 or NR1B3 
(FANTHOM5 dataset; http://www.proteinatlas.org/ENSG00000077092-RARB/tissue).  
 
RAR-related orphan receptor-γ (NR1F3)  
Retinoid-related orphan receptor γ (ROR-γ, encoded by RORC) plays a key role in thymocyte 
development and function, including differentiation of the Th17 cell subset.  Recently, homozygous 
pathogenic variants in RORC, causing disruption of both the ROR-γ and ROR-γ-t isoforms, have been 
reported in seven individuals from three unrelated consanguineous pedigrees with 
immunodeficiency (47).  These families – from Palestine, Chile and Saudi Arabia – have evidence of 
chronic mucocutaneous candidiasis (due to IL-17A and IL-17F deficiency) combined with 
susceptibility to mycobacterial disease and disseminated infections following Bacillus Calmette-
Guérin (BCG) vaccines. Patients also all had a small thymus.  
 
Photoreceptor-specific nuclear receptor (NR2E3) 
Photoreceptor-specific nuclear receptor (PNR, encoded by NR2E3) is involved in retinal 
photoreceptor cell differentiation and degeneration, and its disruption results in retinal 
degeneration in the mouse (rd7). Pathogenic variants in NR2E3 cause enhanced S-cone syndrome 
(ESCS) (48), an inherited retinal disorder characterized by increased visual function of the minority S 
(blue) cones and decreased L/M (red/green) cone and rod function. These findings likely represent 
increased S-cone proliferation at the expense of other cell types during cell fate determination. 
Patients typically develop night blindness and evidence of retinitis pigmentosa (RP). Autopsy studies 
have shown absence of rods and retinal disorganization and degeneration (49).  
 
Amongst pathogenic variants in NR2E3 reported to cause ESCS, homozygous p.Arg311Gln variants 
are most common and represent a hotspot for disease amongst the Crypto-Jewish population in 
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Portugal (50). The same change is also associated with Golgmann-Favre syndrome, a more severe 
form of ESCS (47). Variants in NR2E3 are also found in autosomal-recessive and -dominant forms of 
RP (51, 52). Approximately 3% of dominantly inherited RP is due to a heterozygous PNR mutation 
(p.Gly56Arg) in the first zinc finger of the DBD, exhibiting dominant-negative activity (52, 53). Other 
variants cause altered cellular localization or homo- or hetero-dimerization with TLX/NR2E1 and 
RXRα/NR2C1 (54, 55). Another NR, RevErbα/NR1D1, has been used to potentially “rescue” disease 
progression in the rd7 mouse (56). 
 
Chicken ovalbumin upstream promoter transcription factor I (NR2F1)  
Chicken ovalbumin upstream promoter transcription factor I (COUPTF-I) is widely expressed in 
many tissues with strong expression in the brain and peripheral nervous system and has a potential 
role in regionalization of the neocortex and axonal projection. In humans, NR2F1 haploinsufficiency 
and de novo heterozygous mutations in NR2F1 have been reported in patients with Bosch-Boonstra-
Schaaf optic atrophy syndrome (BBSOAS) (57, 58). Additional characteristics include developmental 
delay and variable, non-specific facial features. Most missense mutations (p.Arg112Lys, p.Ser113Arg, 
p.Arg115Pro) cluster in the DBD and may be associated with a more severe phenotype (58, 59). 
Other features reported recently include hypotonia, oromotor dysfunction, thinning of the corpus 
callosum, seizures, autistic spectrum disorder and hearing impairment (59). 
 
COUPTF-II (NR2F2)  
COUPTF-II plays a role in angiogenesis, vascular remodeling and heart development, as well as in 
more widespread regulation of cell fate during embryonic development. Recently, heterozygous 
variants in NR2F2 have been reported in patients with a range of congenital cardiac disease 
phenotypes (60). In one family, a 3-bp duplication in NR2F2 segregated with multiple cardiac defects 
(atrioventricular septal defect (AVSD), aortic stenosis/VSD, tetralogy of Fallot), whereas other 
heterozygous missense mutations or deletions of NR2F2 have been associated with AVSD, 
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hypoplastic left heart syndrome or aortic coarctation (56). Congenital diaphragmatic hernia (CDH) 
may be an association in mice and humans (61).  
 
Rev-erb-β (NR1D2) 
Rev-erb-β has several proposed actions including being a potential repressor of gene transcription. 
Recently, a de novo heterozygous mutation in NR1D2 was found in one individual with congenital 
heart disease (AVSD)  (62). This variant (p.Arg175Trp) affects binding to the DNA minor groove and 
impairs transcriptional repression. Detailed analysis of Nr1d2-/- mice indicated a similar phenotype 
(62). As this is a very recent observation, the true contribution of Rev-erb-β to developmental heart 
defects is not yet known.  
 
Estrogen-related receptor-β (NR3B2) 
Estrogen-related receptor-β (ERR-β) has structural homology to the ERs and binds ER response 
elements, but is not activated by estrogens. ERR-β plays a role in placental development and is 
expressed in several tissues such as the inner ear during development and postnatal life. (Nucl 
Recept Signal. 2016 Jun 21;14:e002. doi: 10.1621/nrs.14002. eCollection 2016. Estrogen-related 
receptor β (ERRβ) - renaissance receptor or receptor renaissance? Divekar SD, Tiek DM, Fernandez A, 
Riggins RB). Homozygous disruption of ESRRB was first reported in a large consanguineous Turkish 
family with autosomal-recessive non-syndromic hearing loss (type 35) (63). Homozygous point 
mutations in the DBD and more often in the “ligand”-binding domain of ERR-β have also been 
reported as a rare cause of non-syndromic hearing loss, often in consanguineous families (63). A 
potential link between disruption of ESRRB and dental caries has also been proposed (64).  
 
Farnesoid X receptor (NR1H4) 
Farnesoid X receptor (FXR), a bile acid-activated NR, is a key mediator of bile acid homeostasis, 
regulating target genes that mediate hepatic export (e.g. ABCB11, bile salt export pump; ABCB4, 
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multidrug resistance protein 3), biosynthesis (e.g. CYP7A) or enterohepatic circulation (e.g. NTCP, 
IBABP) of bile acids, limiting their intrinsic hepatocellular toxicity. 
 
Four different heterozygous variants in the FXR gene (-1g>t, p.Met1Val, p.Trp80Arg, p.Met173Thr) 
reducing its expression or transcriptional activity were identified from screening 92 women with 
intrahepatic cholestasis of pregnancy (ICP), a disorder characterized by late gestational pruritus and 
abnormal maternal and fetal liver function, predisposing to fetal distress and prematurity (65). The 
heterozygous -1G>T variant was subsequently identified in an unrelated ICP case (66). 
 
Progressive familial intrahepatic cholestasis (PFIC), comprises three subtypes known to be associated 
with mutations in transport proteins (PFIC-1: ATP8B1; PFIC-2: ABCB11/BSEP; PFIC-3: ABCB4), but 
30% of cases are idiopathic. FXR variants have recently been identified in four children with severe, 
neonatal cholestasis progressing to liver failure that was terminal or required transplantation. A 
homozygous, premature stop mutation (p.Arg176*) abrogating DNA binding and function was 
identified in one family and compound heterozygosity for an in-frame DBD insertion 
(pTyr139_Asn140insLys). A 31kB deletion encompassing the first two coding exons of NR1H4 was 
identified in a second family. Similar to previous PFIC cases with defective bile salt export pump 
(BSEP, a known FXR target), cholestasis was associated with low/normal gamma-glutamyl 
transferase (GGT) levels and reduced BSEP expression. Severe vitamin K-independent coagulopathy, 
attributed to reduced FXR-dependent clotting factor levels, and reduced circulating levels of other 
FXR-dependent hormones and metabolites may represent other distinctive, diagnostically useful, 
biomarkers (67). 
 
Hepatocyte nuclear factor 4α (NR2A1) 
Hepatocyte nuclear factor 4α (HNF4α) controls gene expression in the liver (~40% of actively 
transcribed genes) and pancreas (11% of islet cell genes) and regulates pathways of hepatic 
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gluconeogenesis and pancreatic insulin secretion [Editor’s note: Please provide references for this 
statement.] 
 
Maturity-onset diabetes of the young (MODY), usually defined as diabetes mellitus (diagnosed 
before age 25 years) with negative islet cell autoantibodies, is most commonly (~50% of cases) due 
to mutations in HNF1α (MODY type 3), a homeobox family transcription factor, with HNF4A variants 
accounting for a further 10% of cases (MODY type 1). Approximately 100 different heterozygous 
mutations (58% missense; 20% frameshift or premature stop; 5% splice site), localizing to HNF4A 
coding exons have been recorded in this dominantly inherited disorder; a further 5% of variants 
localize to the pancreatic P2 promoter region of HNF4A, disrupting known tissue-specific 
transcription factor binding sites (68). Some HNF4α mutations, even those located outside the 
canonical DBD, compromise a protein interface in the HNF4α homodimer bound to DNA (69), with 
other variants disrupting transactivation, nuclear localization, or protein stability. Due to the large 
number of HNF4α-regulated target genes in liver and pancreas, it has been postulated that 
haploinsufficiency, with loss of even a fraction of functional receptor homodimers, mediates MODY 
(70). 
 
In addition to young age of diagnosis and a family history of early-onset diabetes, reduced serum 
ApoA2 (known to be HNF4α-regulated) and triglyceride levels and exquisite sensitivity to 
sulfonylurea drug therapy may be useful markers of HNF4α MODY (71). HNF4A mutation carriage is 
also associated with excess insulin secretion, resulting in macrosomia and neonatal hyperinsulinemic 
hypoglycaemia (HH) in up to 50% of babies; the latter mandates neonatal surveillance of affected 
pregnancies because HH can be either mild and transient or more severe, requiring treatment with 
diazoxide (72). In addition to neonatal hyperinsulinism and macrosomia, renal proximal tubulopathy 
(Fanconi syndrome) with raised urinary calcium, phosphate and oxalate causing nephrocalcinosis has 
been recorded in patients with a specific HNF4α mutation (p.Arg76Trp) (73). 
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GWAS do show linkage of common variants around the HNF4A locus with T2D; a rare variant 
(p.Thr130Ile) in HNF4A confers modest (1.2 fold) risk of T2D and is associated with HDL cholesterol 
levels (68). 
 
PPARγ (NR1C3)  
PPARγ is essential for adipocyte differentiation but also regulates target genes that mediate 
triglyceride hydrolysis and fatty acid and glycerol uptake, together with genes involved in fatty acid 
re-esterification and lipid storage (74). Heterozygous, missense PPARG mutations (p. Pro467Leu, 
Val290Met), impairing its ligand-dependent transcriptional activity, were first identified in patients 
with severe insulin resistance (IR) and early-onset T2D (75); subsequently, the phenotype was 
recognized to encompass a distinctive pattern of partial lipodystrophy. Additional features (hepatic 
steatosis, dyslipidaemia) likely reflect impaired ability to buffer dietary lipid load, with tissue 
lipotoxicity mediating IR; the resulting hyperinsulinemia mediates polycystic ovarian dysfunction and 
acanthosis nigricans. Hypertension occurring independent of diabetic comorbidities is also a feature, 
suggesting a direct role for PPARγ in control of vascular tone (74). 
 
Rare heterozygous PPARG variants associated with lipodystrophic IR localize to the LBD or DBD, 
disrupting either DNA binding or ligand-dependent transcription activation functions. Additionally, 
mutant receptors inhibit function of their wild-type counterparts in a dominant-negative manner 
(76). In a large, digenic kindred, PPARγ haploinsufficiency alone did not mediate IR, but acted in 
concert with a PPP1R3A mutation that affects muscle glycogen synthesis (77). Whole exome 
sequencing of around 9,000 individuals with T2D identified nine functionally deleterious, rare PPARG 
variants conferring substantial disease risk; however, it could not be ascertained whether adipose 
mass was reduced in these subjects (78). A common PPARG variant (p.Pro12Ala), occurring with 
varying frequency (2 to 18%) in different ethnic groups, is associated with a reduction in T2D risk (OR 
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0.86); conversely, the Pro12 allele is present in 80% of humans and can increase population T2D risk 
by up to 25%. Reduced target gene activation and induction of adipogenesis by the Ala12 PPARγ 
variant may lower adipose mass and improve insulin sensitivity in carriers, forming the basis of its 
protective effect (79).  A rare variant (p.Pro113Gln) in the PPARγ amino-terminal domain, exhibiting 
gain of transcriptional function, was documented in four obese, but paradoxically diabetic, German 
subjects, but this or similar variants have not been found in other obese populations, suggesting a 
strong founder effect (76). 
 
Small heterodimeric partner (NR02B)  
Small heterodimer partner (SHP, NR0B2) is an atypical orphan NR that has a ligand-like binding 
domain with sequence homology to other NRs, but a truncated amino-terminal region lacking a true 
DBD. Heterozygous NROB2 variants with diminished ability to inhibit HNF4α function were reported 
in 7% of Japanese patients with early-onset T2D, mild/moderate obesity and increased birth weight 
(80). A separate study documented loss-of-function NR0B2 variants in 2.4% (19/805) of Japanese 
type 2 diabetics, but also in 0.8% (6/752) nondiabetic controls (81). In contrast, studies in different 
populations have not consistently found such high enrichment for rare SHP variants in cohorts with 
obesity or diabetes (82-85).  
 
CONCLUSIONS  
The identification of naturally occurring NR mutations has provided insights into their structure and 
function, but there are still many NRs where an associated disorder has not yet been discovered. 
Looking to the future, exome or genome sequencing may uncover association of NR gene variants 
with unexpected phenotypes or disorders not readily predicted from their known roles in 
physiological or developmental processes. In other situations, the phenotype might be subtle or 
even embryonic lethal. These technologies will also identify genetic variants whose functional 
consequences are uncertain, emphasizing the need to develop relevant, high-throughput assays of 
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variant NR function that can accurately predict their pathogenic significance, as has been described 
recently for PPARG (86).  
 
With disorders of many classical NRs associated with changes in hormone levels linked to their 
cognate ligands, it is likely that defects in orphan receptors are also accompanied by distinctive 
changes in circulating metabolites or proteins. Metabolomic or proteomic profiling of case cohorts 
with defined NR gene defects may discern characteristic biochemical signatures, enabling better 
diagnosis of associated disorders or providing clues to the identification of unknown orphan 
receptor ligands. 
 
A subset of individuals with typical clinical or biochemical features suggestive of disordered NR 
action do not have mutations in NR proteins and it is possible that variants in non-coding regions of 
the genome affecting function of enhancer regions or involving epigenetic modification of chromatin 
or non-coding RNAs account for such cases. Alternatively, it is possible that defects in genes 
encoding NR cofactor proteins could be associated with such phenotypes. With our increasing 
knowledge of the human genome and application of high throughput technologies to genome 
analysis and small molecule screening, the next 30 years are likely to be an equally exciting time for 
human NR research. 
 
ACKNOWLEDGMENTS 
Our research is supported by funding from the Wellcome Trust (Investigator Award 095564/Z/11/Z 
to KC; Senior Research Fellowship in Clinical Science 098513/Z/12/Z to JCA; Investigator Award 
100237/Z/12/Z to JS), the National Institute for Health Research Biomedical Research Centre at 
Cambridge (KC) or at Great Ormond St Hospital for Children NHS Foundation Trust and University 
College London (JCA). JS is a Royal Society Wolfson Research Merit Award Holder. 
  
23 
 
REFERENCES 
1. Gurnell M, Visser TJ, Beck-Peccoz P, Chatterjee VK. Resistance to Thyroid Hormone. In:  Jameson 
JL & DeGroot LJ, eds. Endocrinology 7th ed. 2015: 1648-1665. 
2. Takeda K, Sakurai A, De Groot LJ, et al. Recessive inheritance of thyroid hormone resistance  
caused by complete deletion of the protein-coding region of the thyroid hormone receptor-β gene. J  
Clin Endocrinol Metab 1992; 74:49–55. 
3. Ferrara AM, Onigata K, Ercan O, et al. Homozygous thyroid hormone receptor β-gene mutations  
in resistance to thyroid hormone: three new cases and review of the literature. J Clin Endocrinol  
Metab 2012; 97:1328-1336. 
4. Bochukova E*, Schoenmakers N*, Agostini M, et al.  A dominant negative mutation in the thyroid 
hormone receptor alpha gene. N Engl J Med 2012;366:243-249 (*coequal first authors). 
5. Moran C and Chatterjee VK. Resistance to Thyroid Hormone due to defective thyroid receptor 
alpha. Best Pract Res Clin Endocrinol Metab 2015;29:647-657. 
6. Moran C*, Agostini M*, Visser WE et al.  Resistance to Thyroid Hormone caused by a mutation in 
thyroid hormone receptor (TR) alpha1 and TRalpha2: clinical, biochemical and genetic analyses of 
three related patients.  Lancet Diabetes Endocrinol 2014;2:619-626 (*coequal first authors).  
7. Feldman D, Malloy PJ.  Mutations in the vitamin D receptor and hereditary vitamin D-resistant 
rickets.  Bonekey Rep 2014;3:510 doi: 10.1038/bonekey.2014.5. eCollection 2014. 
8. Malloy PJ, Zhou Y, Wang J, Hiort O, Feldman D.  Hereditary Vitamin D-Resistant Rickets (HVDRR) 
owing to a heterozygous mutation in the Vitamin D receptor.  J Bone Miner Res 2011;26:2710-2718. 
9. Nakabayashi M, Tsukahara Y, Iwasaki-Miyamoto I, et al. Crystal structures of Hereditary Vitamin 
D-Resistant Rickets-associated vitamin D receptor mutants R270L and W282R bound to 1,25-
dihydroxyvitamin D3 and synthetic ligands.  J Med Chem 2013;56:6745-6760. 
10. Malloy PJ, Feldman D.  The role of vitamin D receptor mutations in the development of alopecia.  
Mol Cell Endocrinol 2011;347:90-96. 
 
24 
 
 
11. Hurley DM, Accili D, Stratakis CA et al. Point mutation causing a single amino acid substitution in 
the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J 
Clin Invest. 1991:87: 680-686. 
12. Nicolaides NC, Charmandari E. Chrousos syndrome: from molecular pathogenesis to therapeutic 
management. Eur J Clin Invest. 2015;45(5):504-514.  
13. Kino T, Stauber RH, Resau JH, Pavlakis GN, Chrousos GP. Pathologic human GR mutant has a 
transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: 
importance of the ligand-binding domain for intracellular GR trafficking. J Clin Endocr Metab 
2001:86: 5600-5608. 
14. Charmandari E, Kino T, Souvatzoglou E, Vottero A, Bhattacharyya N, Chrousos GP. Natural 
glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, 
genetic transmission, and clinical phenotype. J Clin Endocrinol Metab. 2004;89(4):1939-1949. 
15. Charmandari E, Ichijo T, Jubiz W et al. A novel point mutation in the amino terminal domain of 
the human glucocorticoid receptor (hGR) gene enhancing hGR-mediated gene expression. J Clin 
Endocrinol Metab. 2008;93(12):4963-4968.  
16. Geller DS, Rodriguez-Soriano J, Vallo Boado A et al. Mutations in the mineralocorticoid receptor 
gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998;19(3):279-281. 
17. Pujo L, Fagart J, Gary F et al. Mineralocorticoid receptor mutations are the principal cause of 
renal type 1 pseudohypoaldosteronism. Hum Mutat. 2007;28(1):33-40. 
18. Riepe FG, Finkeldei J, de Sanctis L et al. Elucidating the underlying molecular pathogenesis of 
NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol 
Metab 2006;91(11):4552-4561.  
19. Fernandes-Rosa FL, Hubert EL, Fagart J et al. Mineralocorticoid receptor mutations differentially 
affect individual gene expression profiles in pseudohypoaldosteronism type 1. J Clin Endocrinol 
Metab 2011;96(3):E519-27. 
25 
 
20. Geller DS, Farhi A, Pinkerton N et al. Activating mineralocorticoid receptor mutation in 
hypertension exacerbated by pregnancy. Science 2000;289(5476):119-123. 
21. Smith EP, Boyd J, Frank GR et al. Estrogen resistance caused by a mutation in the estrogen-
receptor gene in a man. New Engl J Med. 1994;331:1056-1061. 
22. Smith EP, Specker B, Bachrach BE et al. Impact on bone of an estrogen receptor-alpha gene loss 
of function mutation. J Clin Endocr Metab. 2008;93:3088-3096. 
23. Quaynor SD, Stradtman EW Jr, Kim HG et al. Delayed puberty and estrogen resistance in a 
woman with estrogen receptor alpha variant. New Engl J Med. 2013;369:164-171. 
24. Bernard V, Kherra S, Francou B et al. Familial multiplicity of estrogen insensitivity associated with 
a loss-of-function ESR1 mutation. J Clin Endocrinol Metab 2016; doi: 10.1210/jc.2016-2749 
25. Lubahn DB, Brown TR, Simental JA et al. Sequence of the intron/exon junctions of the coding 
region of the human androgen receptor gene and identification of a point mutation in a family with 
complete androgen insensitivity. Proc Natl Acad Sci USA 1989;86:9534-9538. 
26. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J. Androgen 
insensitivity syndrome. Lancet 2012;380(9851):1419-1428.  
27. McPhaul MJ, Marcelli M, Tilley WD, Griffin JE, Isidro-Gutierrez RF, Wilson JD. Molecular basis of 
androgen resistance in a family with a qualitative abnormality of the androgen receptor and 
responsive to high-dose androgen therapy. J Clin Invest 1991;87:1413-1421. 
28. Ferlin A, Vinanzi C, Garolla A et al. Male infertility and androgen receptor gene mutations: clinical 
features and identification of seven novel mutations. Clin Endocrinol (Oxf) 2006;65(5):606-610. 
29. Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M. The androgen receptor gene mutations 
database: 2012 update. Hum Mutat 2012;33(5):887-94. 13. 
 
NEW REF : (http://androgendb.mcgill.ca/) 
 
26 
 
30. Hornig NC, Ukat M, Schweikert HU et al. Identification of an AR mutation-negative class of 
Androgen Insensitivity by determining endogenous AR activity. J Clin Endocrinol Metab 
2016;101(11):4468-4477. 
31. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene 
mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352: 77–79 
 
NEW REF  
Spinal and Bulbar Muscular Atrophy. 
La Spada A. 
In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, 
Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of 
Washington, Seattle; 1993-2017. 
1999 Feb 26 [updated 2017 Jan 26]. 
 
 
32. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding 
steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 
1999;22(2):125-126. 
33. Achermann JC, Ozisik G, Ito M et al. Gonadal determination and adrenal development are 
regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. J Clin 
Endocrinol Metab 2002;87(4):1829-1833. 
34. Suntharalingham JP, Buonocore F, Duncan AJ, Achermann JC. DAX-1 (NR0B1) and steroidogenic 
factor-1 (SF-1, NR5A1) in human disease. Best Pract Res Clin Endocrinol Metab 2015;29(4):607-619. 
35. Lin L, Philibert P, Ferraz-de-Souza B et al. Heterozygous missense mutations in steroidogenic 
factor 1 (SF1/Ad4BP, NR5A1) are associated with 46,XY disorders of sex development with normal 
adrenal function. J Clin Endocrinol Metab 2007;92(3):991-999. 
27 
 
36. Bashamboo A, Ferraz-de-Souza B, Lourenço D et al. Human male infertility associated with 
mutations in NR5A1 encoding steroidogenic factor 1. Am J Hum Genet 2010;87(4):505-512. 
37. Lourenço D, Brauner R, Lin L et al. Mutations in NR5A1 associated with ovarian insufficiency. N 
Engl J Med 2009;360(12):1200-1210. 
38. Bashamboo A, Donohoue PA, Vilain E et al. A recurrent p.Arg92Trp variant in steroidogenic 
factor-1 (NR5A1) can act as a molecular switch in human sex development. Hum Mol Genet 
2016;25(16):3446-3453. 
39. Zanaria E, Muscatelli F, Bardoni B et al. An unusual member of the nuclear hormone receptor 
superfamily responsible for X-linked adrenal hypoplasia congenita. Nature 1994;372(6507):635-41. 
40. Muscatelli F, Strom TM, Walker AP et al. Mutations in the DAX-1 gene give rise to both X-linked 
adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature 1994;372(6507):672-
676. 
41. Achermann JC, Ito M, Silverman BM et al. Missense mutations cluster within the carboxyl-
terminal region of DAX-1 and impair transcriptional repression. J Clin Endocrinol Metab 
2001;86(7):3171-3175. 
42. Tabarin A, Achermann JC, Recan D et al. A novel mutation in DAX1 causes delayed-onset adrenal 
insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest 2000;105(3):321-8. 
43. Ozisik G, Mantovani G, Achermann JC et al. An alternate translation initiation site circumvents an 
amino-terminal DAX1 nonsense mutation leading to a mild form of X-linked adrenal hypoplasia 
congenita. J Clin Endocrinol Metab 2003;88(1):417-423. 
44. Scheys J, Heaton JH, Hammer GD. Evidence of adrenal failure in aging Dax1-deficient mice. 
Endocrinology 2011;152:3430–3439. 
45. Srour M, Chitayat D, Caron V et al. Recessive and dominant mutations in retinoic acid receptor 
beta in cases with microphthalmia and diaphragmatic hernia. Am J Hum Genet 2013;93(4):765-772. 
46. Slavotinek AM, Garcia ST, Chandratillake G et al. Exome sequencing in 32 patients with 
anophthalmia/microphthalmia and developmental eye defects. Clin Genet 2015;88(5):468-73.  
28 
NEW REF (FANTHOM5 dataset; http://www.proteinatlas.org/ENSG00000077092-RARB/tissue). 
47. Okada S, Markle JG, Deenick EK et al. IMMUNODEFICIENCIES. Impairment of immunity to
Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science 2015;349(6248):606-
613. 
48. Haider NB, Jacobson SG, Cideciyan AV et al. Mutation of a nuclear receptor gene, NR2E3, causes
enhanced S cone syndrome, a disorder of retinal cell fate. Nature Genet 2000;24:127-131. 
49. Milam AH, Rose L, Cideciyan AV et al. The nuclear receptor NR2E3 plays a role in human retinal
photoreceptor differentiation and degeneration.  Proc Natl Acad Sci U S A 2002;99:473-478. 
50. Gerber S, Rozet JM, Takezawa SI et al. The photoreceptor cell-specific nuclear receptor gene
(PNR) accounts for retinitis pigmentosa in the Crypto-Jews from Portugal (Marranos), survivors from 
the Spanish Inquisition. Hum Genet 2000;107:276-284. 
51. Bernal S, Solans T, Gamundi MJ et al. Analysis of the involvement of the NR2E3 gene in
autosomal recessive retinal dystrophies. Clin Genet 2008;73:360-366. 
52. Coppieters F, Leroy BP, Beysen D et al. Recurrent mutation in the first zinc finger of the orphan
nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. Am J Hum Genet 
2007;81:147-157. 
53. Blanco-Kelly F, García Hoyos M, Lopez Martinez MA et al. Dominant Retinitis Pigmentosa,
p.Gly56Arg Mutation in NR2E3: Phenotype in a Large Cohort of 24 Cases. PLoS One 
2016;11(2):e0149473. 
54. Kanda A, Swaroop A. A comprehensive analysis of sequence variants and putative disease-
causing mutations in photoreceptor-specific nuclear receptor NR2E3. Mol Vis 2009;15:2174-2184. 
29 
55. von Alpen D, Tran HV, Guex N et al. Differential dimerization of variants linked to enhanced S-
cone sensitivity syndrome (ESCS) located in the NR2E3 ligand-binding domain. Hum Mutat 
2015;36(6):599-610.  
56. Cruz NM, Yuan Y, Leehy BD et al. Modifier genes as therapeutics: the nuclear hormone receptor
Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease. PLoS One 2014:9(1);e87942. 
57. Al-Kateb H, Shimony JS, Vineyard M,  Manwaring L, Kulkarni S, Shinawi M. NR2F1
haploinsufficiency is associated with optic atrophy, dysmorphism and global developmental delay. 
Am J Med Genet A 2013;161A(2):377-381. 
58. Bosch DG, Boonstra FN, Gonzaga-Jauregui C et al. NR2F1 mutations cause optic atrophy with
intellectual disability. Am J Hum Genet 2014:94;303-309. 
59. Chen CA, Bosch DG, Cho MT et al. The expanding clinical phenotype of Bosch-Boonstra-Schaaf
optic atrophy syndrome: 20 new cases and possible genotype-phenotype correlations. Genet Med 
2016;18(11):1143-1150.  
60. Al Turki S, Manickaraj AK, Mercer CL et al. Rare variants in NR2F2 cause congenital heart defects
in humans. Am J Hum Genet 2014:94;574-585. 
61. High FA, Bhayani P, Wilson JM, Bult CJ, Donahoe PK, Longoni M.  De novo frameshift mutation in
COUP-TFII (NR2F2) in human congenital diaphragmatic hernia. Am J Med Genet A 2016;170(9):2457-
2461. 
62. Priest JR, Osoegawa K, Mohammed N, et al. De novo and rare variants at multiple loci support
the oligogenic origins of atrioventricular septal heart defects. PLoS Genet 2016;12:e1005963. 
Nucl Recept Signal. 2016 Jun 21;14:e002. doi: 10.1621/nrs.14002. eCollection 2016. 
Estrogen-related receptor β (ERRβ) - renaissance receptor or receptor renaissance? 
Divekar SD1, Tiek DM1, Fernandez A1, Riggins RB1. 
30 
63. Collin RWJ, Kalay E, Tariq M et al. Mutations of ESRRB encoding estrogen-related receptor beta
cause autosomal-recessive nonsyndromic hearing impairment DFNB35. Am J Hum Genet 
2008;82:125-138.  
64. Weber ML, Hsin HY, Kalay E et al. Role of estrogen related receptor beta (ESRRB) in DFN35B
hearing impairment and dental decay. BMC Med Genet 2014;15:81. 
65. Van Mil SWC, Milona A, Dixon PH, et al.  Functional variants of the central bile acid sensor FXR
identified in intrahepatic cholestasis of pregnancy.  Gastroenterology 2007;133:507-516. 
66. Davit-Spraul A, Gonzales E, Jacquemin E.  NR1H4 analysis in patients with progressive familial
intrahepatic cholestasis, drug-induced cholestasis or intrahepatic dholestasis of pregnancy unrelated 
to ATP8B1, ABCB11 and ABCB4 mutations.  Clin Res Hepatol Gastroenterol 2012;36:569-573. 
67. Gomez-Ospina N, Potter CJ, Ziao R, et al.  Mutations in the nuclear bile acid receptor FXR cause
progressive familial intrahepatic cholestasis.  Nat Commun 2016;7:10713 doi: 
10.1038/ncomms10713. 
68. Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S.  Mutations in the genes
encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset 
diabetes of the young and hyperinsulinemic hypoglycaemia.  Hum Mutat 2013;34:669-685. 
69. Chandra V, Huang P, Potluri N, Wu D, Kim Y, Rastinejad F.  Multidomain integration in the
structure of the HNF-4α nuclear receptor complex.  Nature 2013;495:394-398. 
70. Shih DQ, Dansky JM, Fleisher M, Assmann G, Fajans SS, Stoffel M.  Genotype/phenotype
relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein 
(AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes 2000;49:832-837. 
71. Pearson ER, Pruhova S, Tack CJ et al.  Molecular genetics and phenotypic characteristics of MODY
caused by hepatocyte nuclear factor 4alpha mutations in a large European collection.  Diabetologia 
2005;48:878-885. 
72. Pearson ER, Boj SF, Steele AM et al. Macrosomia and hyperinsulinaemic hypoglycaemia in
patients with heterozygous mutations in the HNF4A gene. PLoS Med 4:e118 
31 
73. Hamilton AJ, Bingham C, McDonald TJ et al.  The HNF4A R76W mutation causes atypical
dominant Fanconi syndrome in addition to a β cell phenotype.  J Med Genet 2014;51:165-169. 
74. Semple RK, Chatterjee VKK, O’Rahilly S. PPARγ and human metabolic disease. J Clin Invest 2006;
116: 581-589. 
75. Barroso I, Gurnell M, Crowley VEF, et al.  Dominant negative mutations in human PPARγ are
associated with severe insulin resistance, diabetes mellitus and hypertension.  Nature 1999;402:880-
883. 
76. Jeninga EH, Gurnell M, Kalkhoven E.  Functional implications of genetic variation in human
PPARγ.  Trends Endocrinol Metab 2009;20:380-387. 
77. Savage DB, Agostini M, Barroso I et al. Digenic inheritance of severe insulin resistance in a human
pedigree. Nat Genet 2002; 31:379-384. 
78. Majithia AR, Flannick J, Shahinian P, et al.  Rare variants in PPARG with decreased activity in
adipocyte differentiation are associated with increased risk of type 2 diabetes.  Proc Natl Acad Sci U 
S A 2014;111:13127-13132. 
79. Gouda HN, Sagoo GS, Harding A-H et al. The association between the Peroxisome Proliferator-
Activated Receptor g2 (PPARG2) Pro12Ala Gene Variant and type 2 diabetes mellitus: A HuGE review 
and meta-analysis. Am J Epidemiol 2010; 171:645-655. 
80. Nishigori H, Tomura H, Tonooka N et al. Mutations in the small heterodimer partner gene are
associated with mild obesity in Japanese subjects. Proc Natl Acad Sci U S A. 2001;98(2):575-580. 
81. Enya M, Horikawa Y, Kuroda E et al. Mutations in the small heterodimer partner gene increase
morbidity risk in Japanese type 2 diabetes patients. Hum Mutat 2008;29(11):E271-277. 
82. Mitchell SM, Weedon MN, Owen KR et al. Genetic variation in the small heterodimer partner
gene and young-onset type 2 diabetes, obesity, and birth weight in U.K. subjects. Diabetes 
2003;52(5):1276-1279. 
32 
83. Hung CC, Farooqi IS, Ong K et al. Contribution of variants in the small heterodimer partner gene
to birthweight, adiposity, and insulin levels: mutational analysis and association studies in multiple 
populations. Diabetes 2003;52(5):1288-1291. 
84. Echwald SM, Andersen KL, Sørensen TI et al. Mutation analysis of NR0B2 among 1545 Danish
men identifies a novel c.278G>A (p.G93D) variant with reduced functional activity. Hum Mutat 
2004;24(5):381-387. 
85. Ahituv N, Kavaslar N, Schackwitz W et al. Medical sequencing at the extremes of human body
mass. Am J Hum Genet 2007;80(4):779-791. 
86. Majithia AR, Tsuda B, Agostini M, et al.  Prospective functional classification of all possible
missense variants in PPARG.  Nat Genet 2016;48:1570-1575. 
37 
FIGURE LEGENDS 
Figure 1. A timeline of identification of defects in human NR genes. 
The year when the first monogenic disorder associated with each nuclear receptor was published is 
shown on the x-axis. The cumulative number of human nuclear receptors associated with a disorder 
is shown by the line (y-axis). 
Figure 2. Molecular mechanisms of disrupted NR action. 
A. Mechanisms whereby NR gene and protein changes can alter function. Gene deletion or 
mutations causing mRNA instability or impairing key cellular functions can cause loss-of-function 
(left side, shown in red). Gain of receptor function due to duplication of an NR genomic locus (e.g. 
NR0B1) or ligand binding domain mutation (see also Fig 2A) is also recognized (right side, shown in 
black).    
B. In several disorders, heterozygous receptor mutants (e.g. TRβ, TRα, PPARγ, VDR), inhibit the 
action of their wild type (WT) counterparts in a dominant negative manner. In contrast to WT 
receptor (upper panel), either defective binding of ligand (L) or recruitment of coactivator (CoA) by 
mutant (MUT) receptor impairs its dissociation of corepressor (CoR), mediating constitutive 
repression of target gene expression (lower panel). 
C. Alopecia is not a universal feature of hereditary vitamin D resistance, being associated with VDR 
mutations that disrupt DNA binding, heterodimerization with RXR or cause loss of receptor 
expression, but not with variants exhibiting impaired ligand binding affinity or coactivator 
recruitment. Repression of target genes by unliganded wild type receptor maintains a normal hair 
growth cycle (upper panel), and loss of such inhibition with a subset of VDR mutants (lower panel), is 
thought to mediate this variable phenotype. 
Figure 3. Structural modeling of NR mutations. 
A. Modeling (PDB 2H77 TRα, PDB 1KKQ SMRT), showing that mutation of residues (red spheres) in 
the carboxyterminal region of TRα, which prematurely truncate helix 11 or 12 (left panel), facilitate 
its ability to accommodate corepressor (SMRT, blue) within a groove at the receptor surface (right 
panel).  
B. Modeling (PDB 1RK3, VDR bound to DRIP 205 coactivator) showing that a glutamic acid residue 
(red sphere) (left panel) hydrogen bonds with the peptide backbone of coactivator (green; middle 
panel). Mutation to lysine abolishes this interaction (right panel).   
C. Modeling (PDB 5HCV MR, PDB 5L7E S810L mutant MR), showing that wild type receptor, with 
serine at position 810, accommodates aldosterone via hydrogen bonding (red dotted line) with 
steroid (middle panel), whereas mutant MR with a leucine substitution accommodates progesterone 
via van der Waals (blue dotted line) interaction with steroid.  
D. Modeling (PDB 2FF0) showing SF-1/NR5A1 bound to DNA. R92 makes an extensive hydrogen bond 
network in the minor groove to support monomeric binding. This interaction is disrupted by the 
R92W mutation due to the presence of an indole side-group. 
Figure 1 
0
2
4
6
8
10
12
14
16
18
20
Year first genetic cause published 
T
R
α 
SH
P 
G
R
 
E
R
R
β 
PN
R
 
H
N
F4
α 
FX
R
α 
R
O
R
γ 
P
P
A
R
γ,
 S
F-
1 
R
A
R
β 
C
O
U
P-
TF
I, 
C
O
U
P-
TF
II 
M
R
 
E
R
α,
 D
A
X
-1
 
N
um
be
r o
f n
uc
le
ar
 re
ce
pt
or
s 
VD
R
 
TR
β,
 A
R
 
R
ev
-e
rb
β 
Nuclear receptor gene 
Gene deletion 
 ↓ Nuclear  
localization 
Protein  
aggregation 
↓  DNA-binding 
↓  Ligand-binding 
↓  Co-factor interactions 
↓  Hetero-/homo-dimer 
interactions 
 ↑ Altered LBD and 
gain-of-function 
 Duplication of genomic locus 
(increased copy number) 
Gain-of-function Loss-of-function 
RNA nonsense mediated decay 
Figure 2A 
WT Receptor 
WT RXR 
L 
CoA 
Activation 
HRE TARGET GENE 
MUT Receptor 
RXR 
CoR 
Mut 
o  
HRE TARGET GENE 
 Repression 
Figure 2B 
WT VDR 
RXR WT 
L 
HRE TARGET GENE 
MUT VDR 
RXR 
CoR o  
TARGET GENE   Alopecia 
Normal hair  
growth cycle 
 Repression 
CoR 
 Derepression 
HRE 
WT 
L 
 or 
Mut 
Figure 2C 

Table 1. Overview of pathogenic variants in classic ligand-dependent NRs associated with 
human genetic disorders  
AFirst report shows the year that point mutations in the causative gene were first published. In some 
situations, clinical features of the condition were described previously.  
Glucocorticoid resistance was first reported as a clinical syndrome in 1976 and studied further in 
relation to possible GR insensitivity throughout the 1980s.  
Pseudohypoaldosteronism in infancy was first reported in 1958 and decreased aldosterone binding 
to patient cells, suggesting a defect in the MR, was shown in 1985. 
Androgen insensitivity syndrome was first reported as “testicular feminization syndrome” in 1953 
and identified as an X-linked condition likely due to androgen resistance in the 1960s and 1970s. In 
the 1980s decreased androgen binding to fibroblasts was shown for a subset of individuals with AIS. 
Receptor Original name Official 
name 
HGNC 
gene 
Ligand OMIM First 
reportA 
NumberB Inherited Condition 
TRα Thyroid hormone 
receptor-α 
NR1A1 THRA Thyroid 
hormones 
614450 2012 10 AD Resistance to THα 
TRβ Thyroid hormone 
receptor-β 
NR1A2 THRB Thyroid 
hormones 
188570 1989 100-200 AD Resistance to THβ (dominant) 
274300 1992 5 AR Resistance to THβ (recessive) 
VDR Vitamin D3 
receptor 
NR1I1 VDR Vitamin D, 
1,25-
dihydroxy-
vitamin D3 
277440 1988 10 to 50 AR Vitamin D-resistant rickets 
type IIA 
GR Glucocorticoid 
receptor 
NR3C1 NR3C1 Cortisol 615962 1991 10 to 50 AD, AR Glucocorticoid resistance 
MR Mineralocorticoid 
receptor 
NR3C2 NR3C2 Aldosterone 177735 1998 50 to 100 AD Pseudohypoaldosteronism 
(type I, autosomal dominant) 
605115 2001 1 AD Hypertension with 
exacerbation in pregnancy 
ERα Estrogen receptor-
α 
NR3A1 ESR1 Estradiol 615363 1994 3 AR Estrogen resistance 
AR Androgen receptor NR3C4 AR Testosterone 300068 1989 > 200 XLR Androgen insensitivity 
312300 1991 > 200 XLR Partial androgen insensitivity 
N/A 1994 50 to 100 XLR Mild androgen insensitivity 
(infertility) 
313200 1994 > 200 XLR Kennedy spinal and bulbar 
muscular atrophy 
BNumber reflects either sporadic cases or families with the condition, not total number of affected 
individuals. 
Abbreviations: OMIM, Online Mendelian Inheritance in Man; AD, autosomal dominant; AR, 
autosomal recessive; XLR, X-linked recessive. 
  
Table 2. Overview of pathogenic variants in orphan or non-classic NRs associated with human 
genetic disorders 
Receptor Original name Official name 
HGNC 
gene Ligand OMIM 
First 
reportA 
NumberB Inherited Condition 
SF1 Steroidogenic factor-1 NR5A1 NR5A1 Orphan 612965 1999 2 AD, AR Primary adrenal insufficiency and gonadal dysgenesis (46,XY) 
     612965 2003 100-200 AD, AR, SLD 46,XY DSD 
     612964 2009 10 to 50 AD, AR Primary Ovarian Insufficiency 
     613957 2010 10 to 50 AD Male factor infertility 
     N/A 2016 10 to 50 AD 46,XX ovotesticular/testicular DSD 
     N/A 2000 2 AD, AR Primary adrenal insufficiency (46,XX) 
DAX-1 
Dosage-sensitive sex 
reversal-adrenal hypoplasia 
congenita critical region on 
the X chromosome, gene 1 
NR0B1 NR0B1 Orphan 300200 1994 > 200 XLR 
X-linked adrenal hypoplasia 
(with hypogonadotropic 
hypogonadism , male infertility) 
     300018 1991 10 to 50 dup 46,XY DSD 
RARβ Retinoic acid receptor-β NR1B2 RARB Retinoic acid 615524 2013 4 AD, AR 
Syndromic microophthalmia 
(type 12), diaphragmatic hernia, 
pulmonary hypoplasia, cardiac 
defects 
RORγ RAR-related orphan receptor-γ NR1F3 RORC Orphan 616622 2015 3 AR Immunodeficiency (type 42) 
PNR Photoreceptor-specific nuclear receptor NR2E3 NR2E3 Orphan 268100 2000 50 to 100 AR 
Enhanced S-cone disease 
(including Goldman-Favre 
syndrome) 
     611131 2007 10 to 50 AR, AD Retinitis pigmentosa (type 37) 
COUP-
TFI 
Chicken ovalbumin 
upstream promoter 
transcription factor I 
NR2F1 NR2F1 Orphan 615722 2014 10 to 50 AD 
Bosch-Boonstra-Schaaf optic 
atrophy syndrome 
(developmental delay) 
COUP-
TFII 
Chicken ovalbumin 
upstream promoter 
transcription factor II 
NR2F2 NR2F2 Orphan 615779 2014 10 to 50 AD Congenital heart defects, multiple (type 4) 
Rev-
erbβC Rev-erbβ NR1D2 NR1D2 Orphan N/A 2016 1 AD
D Congenital heart defects (AVSD) 
ERRβ Estrogen-related receptor-β NR3B2 ESRRB Orphan 608565 2008 < 10 AR Autosomal recessive deafness (type 35) 
FXRα Farsenoid receptor-α NR1H4 NR1H4 Bile acids 617049 2007 < 10 AR 
Intrahepatic cholestasis of 
pregnancy 
Progressive familial intrahepatic 
cholestasis 
HNF4α Hepatocyte nuclear factor 4 receptor-α NR2A1 HNF4A Orphan 125850 1996 100 AD 
MODY type 1 
Hyperinsulinaemic 
hypoglycaemia 
     616026 2014 1 ADD Fanconi renotubular syndrome type 4 with MODY 
PPARγ Peroxisome proliferator activated receptor-γ NR1C3 PPARG 
Fatty acids, 
eicosanoids 604367 1999 10 to 50 ?? 
Familial partial lipodystrophy 
(type 3) 
Digenic severe IR 
 AFirst report shows the year that point mutations in the causative gene were first published. JHH: 
Yes, ideally, they should have their own superscripted callouts. In some situations, clinical features 
of the condition were described previously. For example, X-linked adrenal hypoplasia congenita (X-
linked AHC) causing “cytomegalic” adrenal hypoplasia was first reported in 1948 and the X-linked 
basis identified in the 1970s, followed by reports of gene deletion syndromes involving chromosome 
Xp21 in the 1980s. Enhanced S-cone syndrome was first described in 1990 and thought to be a 
disorder of photoreceptor determination and proliferation in 1995.  
BNumber reflects either sporadic cases or families with the condition, not total number of affected 
individuals. 
CAssociation of mutations in Rev-erbβ (NR1D2) with congenital heart defects is currently based on a 
single case report. 
DInhertiance patterns are tentative, especially when only one individual or family has been reported.  
Abbreviations: OMIM, Online Mendelian Inheritance in Man; N/A, not available; AD, autosomal 
dominant; AR, autosomal recessive; XLR, X-linked recessive; SLD, sex-linked dominant; MODY, 
maturity-onset diabetes of the young; DSD, disorders of/differences in sex development; IR, insulin 
resistance. 
 
 
 
     601665 1998 1 ADD Severe Obesity 
     125853 1998 1 ADD Resistance to T2D 
SHP Small heterodimeric partner NR0B2 NR0B2 Orphan 601665 2001 10 to 50 AD 
Mild obesity, high birth weight 
(T2D) 
